Literature DB >> 22293188

A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats.

Hideyuki Yamawaki1, Minako Takahashi, Masashi Mukohda, Tomoka Morita, Muneyoshi Okada, Yukio Hara.   

Abstract

Nesfatin-1 is a novel adipocytokine which exerts not only anorexigenic but also hypertensive roles through acting on hypothalamus melanocortin-3/4 receptors. Although it is logical to hypothesize that nesfatin-1 could also affect the contractile reactivity of peripheral blood vessels, it still remains to be examined. The present study was performed to test the hypothesis. In both endothelium-intact and -denuded mesenteric artery of rats, acute treatment with nesfatin-1 (10nM, 30min pretreatment) had no influence on the noradrenaline- and 5-hydroxytryptamine-induced concentration-dependent contractions. Chronic treatment of mesenteric artery with nesfatin-1 (10nM, 3days) using organ-culture method had also no influence on the agonists-induced contractions. In contrast, nesfatin-1 (10nM, 30min) significantly inhibited the sodium nitroprusside (SNP)-induced relaxations of smooth muscle in mesenteric artery. A membrane permeable cyclic GMP (cGMP) analog, 8-bromo-cGMP-induced relaxations were not affected by nesfatin-1. Consistently, the SNP-induced cGMP production in smooth muscle was impaired by nesfatin-1. Intravenous application of nesfatin-1 to rats not only increased blood pressure but also impaired the SNP-induced decreases in blood pressure. The present study for the first time reveals that nesfatin-1 affects peripheral arterial blood vessel and inhibits the nitric oxide donor-induced smooth muscle relaxations via impairing the cGMP production. The results are the first to demonstrate that nesfatin-1 modulates blood pressure through directly acting on peripheral arterial resistance.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293188     DOI: 10.1016/j.bbrc.2012.01.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  Visceral adipose tissue-derived serine protease inhibitor prevents the development of monocrotaline-induced pulmonary arterial hypertension in rats.

Authors:  Yuzaburo Sakamoto; Satoshi Kameshima; Chiharu Kakuda; Yuta Okamura; Tomoko Kodama; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  Pflugers Arch       Date:  2017-08-03       Impact factor: 3.657

2.  Increased blood pressure in nesfatin/nuclebindin-2-transgenic mice.

Authors:  Yusaku Mori; Hiroyuki Shimizu; Hideki Kushima; Munenori Hiromura; Michishige Terasaki; Michitaka Tanaka; Aya Osaki; Tsutomu Hirano
Journal:  Hypertens Res       Date:  2017-04-27       Impact factor: 3.872

Review 3.  Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome.

Authors:  Tuba Tekin; Betul Cicek; Nurefsan Konyaligil
Journal:  Eurasian J Med       Date:  2019-08-19

Review 4.  Nesfatin-1 and its effects on different systems.

Authors:  C Ayada; Ü Toru; Y Korkut
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

5.  Nesfatin-1 activates cardiac vagal neurons of nucleus ambiguus and elicits bradycardia in conscious rats.

Authors:  G Cristina Brailoiu; Elena Deliu; Andrei A Tica; Joseph E Rabinowitz; Douglas G Tilley; Khalid Benamar; Walter J Koch; Eugen Brailoiu
Journal:  J Neurochem       Date:  2013-07-19       Impact factor: 5.372

6.  Balanced oxidative status by nesfatin-1 in intestinal ischemia-reperfusion.

Authors:  Ceylan Ayada; Ümran Toru; Osman Genç; Raziye Akcılar; Server Şahin
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 7.  Multi-functional peptide hormone NUCB2/nesfatin-1.

Authors:  Suleyman Aydin
Journal:  Endocrine       Date:  2013-03-23       Impact factor: 3.633

8.  Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome.

Authors:  Peng Shen; Yingying Han; Bo Cai; Yu Wang
Journal:  Sleep Breath       Date:  2014-07-24       Impact factor: 2.816

Review 9.  Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.

Authors:  Sandra Feijóo-Bandín; Diego Rodríguez-Penas; Vanessa García-Rúa; Ana Mosquera-Leal; José Ramón González-Juanatey; Francisca Lago
Journal:  Endocrine       Date:  2015-12-12       Impact factor: 3.633

10.  Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury.

Authors:  T Angelone; E Filice; T Pasqua; N Amodio; M Galluccio; G Montesanti; A M Quintieri; M C Cerra
Journal:  Cell Mol Life Sci       Date:  2012-09-07       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.